WuXi AppTec : Industry Trend and Company Strategy - 2022 Investor Day

2 0 2 2 Wu X i A p p Te c I n v e s t o r D a y

Industry Trend and Company Strategy

Edward Hu

Vice Chairman & Global Chief Investment Officer

"Forward-Looking Statements

This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients' intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Non-IFRS Financial Measures

We provide Non-IFRS gross profit and Non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, listing expenses and issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of intangible assets acquired in business combinations and goodwill impairment. We also provide adjusted Non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture investments and joint ventures. We further provide EBITDA and adjusted EBITDA. Neither of above is required by, or presented in accordance with IFRS.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring,non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such Non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted Non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

01 Industry Trend

02 Company Strategy

03 Company Performance

Notes:

All financials disclosed in this presentation are prepared based on International Financial Reporting Standards (or "IFRSs"). The unit of currency is RMB.

Industry Trend

-- Thriving Industry of CRO & CDMO

Innovation Drives Approval of Novel Drugs for Patients in Need

16 New Drugs have been Approved by FDA in 1H 2022

#	Generic Name (Brand Name)	Company	Indications	Approval Date
1	Vutrisiran (Amvuttra)	Alnylam Pharmaceuticals	For the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults	2022/6/13
2	Tapinarof (Vtama)	Welichem Biotech,	For the topical treatment of plaque psoriasis in adults.	2022/5/24
Dermavant Sciences
3	Tirzepatide (Mounjaro)	Eli Lilly	As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.	2022/5/13
4	Vonoprazan/Amoxicillin/Clarithro Phathom Pharmaceuticals	For the treatment of Helicobacter pylori (H. pylori) infection in adults	2022/5/3
	mycin (Voquezna Triple Pak)
5	Mavacamten (Camzyos)	MyoKardia (BMS)	For the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive	2022/4/28
hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms
6	Oteseconazole (Vivjoa)	Mycovia Pharmaceuticals	To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are	2022/4/26
NOT of reproductive potential
	Lutetium (177Lu) vipivotide	RadioMedix, Endocyte	For the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic
7	castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway	2022/3/23
tetraxetan (Pluvicto)	(Novartis)
	inhibition and taxane-based chemotherapy
8	Ganaxolone (Ztalmy)	Purdue Pharma, Marinus	For the treatment of seizures associated with cyclin-dependentkinase-like 5 (CDKL5) deficiency disorder (CDD)	2022/3/18
Pharmaceuticals	in patients 2 years of age and older
9	Relatlimab/Nivolumab	Bristol-Myers Squibb	For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic	2022/3/18
(Opdualag)	melanoma
10	Pacritinib (Vonjo)	CTI BioPharma	For the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-	2022/2/28
essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109 /L
11	Mitapivat (Pyrukynd)	Agios Pharmaceuticals	For the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency	2022/2/17
12	Sutimlimab (Enjaymo)	iPierian (BMS), Bioverativ	To decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease	2022/2/4
(Sanofi)	(CAD)
13	Faricimab (Vabysmo)	Genentech (Roche)	For the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD) and Diabetic	2022/1/28
Macular Edema (DME)
14	Tebentafusp (Kimmtrak)	Immunocore	For the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma	2022/1/25
15	Abrocitinib (Cibinqo)	Pfizer	For the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately	2022/1/14
controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable
16	Daridorexant (Quviviq)	Actelion (J&J), Idorsia	For the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep	2022/1/7
Pharmaceuticals	maintenance

5 Source: FDA